NCT02392429 2026-03-19
FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
24 trialsNCT07471815 2026-03-13
Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy
Harbin Medical University
Phase 2 Active not recruiting
NCT05763199 2026-03-12
Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy
University of California, Davis
Phase 2 Active not recruiting
NCT05710328 2026-03-02
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT07339488 2026-01-14
ILDR-03
Shantou University Medical College
Phase 2 Active not recruiting
NCT05826964 2026-01-13
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
Phase 2 Active not recruiting
NCT03599752 2026-01-09
Chemotherapy and/or Metastasectomy in Treating Patients With Metastatic Colorectal Adenocarcinoma With Lung Metastases
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02153229 2025-12-26
MPM-PDT
Abramson Cancer Center at Penn Medicine
Phase 2 Active not recruiting
NCT00929214 2025-12-17
Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT01154920 2025-12-17
Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02994069 2025-10-14
Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers
University of Kentucky
Phase 2 Active not recruiting
NCT03283384 2025-09-19
NEOLBC
Borstkanker Onderzoek Groep
Phase 2 Active not recruiting
NCT03070366 2025-09-02
OMET
Groupe Oncologie Radiotherapie Tete et Cou
Phase 2 Active not recruiting
NCT04905316 2025-06-17
CHORUS
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT02122185 2025-06-08
Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
University of Chicago
Phase 2 Active not recruiting
NCT03930498 2025-01-28
Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Active not recruiting
NCT06727357 2024-12-10
Next Generation Sequencing-based "Oncochip" for Therapeutic Decision in Metastatic Breast Cancer. Study SHARP
European Institute of Oncology
Phase 2 Active not recruiting
NCT06667050 2024-10-31
CAPOX Plus Sintilimab and Bevacizumab Biosimilar (IBI305) for Neoadjuvant Treatment of Locally Advanced Gastric Cancer
West China Hospital
Phase 2 Active not recruiting
NCT05400070 2024-10-18
Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC
Tang-Du Hospital
Phase 2 Active not recruiting
NCT03018418 2024-09-19
Proton Therapy in Reducing Toxicity in Anal Cancer
University of Cincinnati
Phase 2 Active not recruiting
NCT04230759 2024-09-19
RADIANCE
Goethe University
Phase 2 Active not recruiting
NCT03700099 2024-04-15
Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide
Instituto do Cancer do Estado de São Paulo
Phase 2 Active not recruiting
NCT03443856 2024-01-05
VESTIGE
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Active not recruiting
NCT05569811 2023-09-21
VALENTINE
SOLTI Breast Cancer Research Group
Phase 2 Active not recruiting